Partial Oral Versus Intravenous Antibiotic Therapy for Endocarditis With Management by a Multidisciplinary Team: A Retrospective Cohort Study - Scorecard - MDSpire
Advertisement
Partial Oral Versus Intravenous Antibiotic Therapy for Endocarditis With Management by a Multidisciplinary Team: A Retrospective Cohort Study
Clinical Scorecard: Comparison of Partial Oral and Intravenous Antibiotic Treatment for Endocarditis Managed by a Multidisciplinary Team: A Retrospective Cohort Analysis
At a Glance
Category
Detail
Condition
Infective Endocarditis (IE)
Key Mechanisms
Partial oral antibiotic therapy as stepdown treatment versus exclusive intravenous antibiotic therapy
Target Population
Patients with definite IE including those with methicillin-susceptible Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, streptococci, and methicillin-resistant Staphylococcus aureus (MRSA); including persons who inject drugs (PWIDs)
Care Setting
Multidisciplinary endocarditis team-managed inpatient and outpatient settings
Key Highlights
Partial oral antibiotic therapy for IE is safe and effective with outcomes comparable to exclusive IV treatment in selected patients.
No significant difference in 90-day relapsed infection or all-cause mortality between oral and IV therapy groups.
Multidisciplinary team approach facilitates patient selection and management, including addiction medicine consultation for patients with substance use disorder.
Guideline-Based Recommendations
Diagnosis
Definite IE diagnosis confirmed via institutional registry and clinical criteria.
Transesophageal echocardiography (TEE) not required prior to oral antibiotic switch in this study.
Management
Patients stable for discharge after at least 10 days of IV antibiotics from blood culture clearance or 7 days post-valve surgery may be offered partial oral antibiotic therapy.
Oral therapy typically involves two agents with different mechanisms for MSSA, CoNS, Enterococcus faecalis, and streptococci; MRSA patients offered oral linezolid monotherapy.
Decisions on antibiotic route, duration, valve surgery, and other interventions made by multidisciplinary endocarditis team.
Monitoring & Follow-up
Regular follow-up and multidisciplinary team review to assess clinical stability and treatment response.
Addiction medicine consultation offered for patients with active substance use disorder or history of injection drug use.
Risks
Older age, acute heart failure, and discharge before medically advised are independent predictors of increased 90-day mortality.
No increased risk of relapse or mortality associated with partial oral therapy compared to IV therapy.
Patient & Prescribing Data
236 patients with definite IE; 143 received IV therapy alone, 93 transitioned to partial oral therapy; included patients with MRSA and PWIDs.
Partial oral therapy did not increase 90-day mortality or relapse rates; valve surgery was more frequent in oral therapy group; oral therapy feasible and effective in real-world multidisciplinary team setting.
Clinical Best Practices
Utilize a multidisciplinary endocarditis team to guide antibiotic route and duration decisions.
Offer addiction medicine consultation to patients with active or prior injection drug use.
Select patients for partial oral therapy after clinical stability and adequate initial IV treatment duration.
Employ oral antibiotic regimens with agents of different mechanisms for non-MRSA pathogens; consider oral linezolid monotherapy for MRSA.
Follow guideline-recommended durations of therapy based on pathogen and clinical status.
by Sami El-Dalati, Bennett Collis, Takaaki Kobayashi, Evan Hall, Talal Alnabelsi, Chloe Cao, Meredith Johnson, John Gurley, Luke Strnad, Corey Adams, Victoria Weaver, Hassan Reda, Michael Sekela, Tessa London, Kara Kennedy, Armaghan-E Rehman Mansoor, David Olafsson, Grant Laugherty, Alyssa Tremblay, Angella Linder, Deborah Gill, Nicholas J Van Sickels, Alexander Pomakov, William Harris, Bobbi Jo Stoner
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
